This Yearbook aims to distinguish those companies that have demonstrated strengths in corporate sustainability
Lack of technology transfer stands out as a formidable barrier
ICRA expects the OPM of the sample set to moderate to 20.2% in FY2023 from 21.5% in FY2022.
The conference brought together over 500 doctors and 150 nutritionists to discuss emerging obesity-related challenges
Pharma and healthcare stocks stay in focus as investors track earnings, USFDA approvals, hospital growth, and global market pressures
Early implementation of West Synchrony S1 platform aims to accelerate biologics and vaccine development while reducing manufacturing risk for biopharma partners
While Drugs for Neglected Diseases initiative (DNDi) drives the R&D for neglected diseases, we collaborate with pharmaceutical companies at multiple stages, including sourcing promising molecules
EUDRAGIT polymers remain a cornerstone technology in oral drug delivery
With big pharma leaning on external pipelines, the company sees opportunity in de-risked, high-impact assets with clear clinical endpoints
Deploys $40 million in Hyderabad; advances APIs, peptides, and global small molecule capabilities
Subscribe To Our Newsletter & Stay Updated
